CardiaMetrics Company Profile

Background

Overview

CardiaMetrics is a French medtech company founded in December 2023, with offices in Caen and Grenoble. The company specializes in developing implantable medical devices designed to assess cardiac function, focusing on the prevention of cardiac decompensations and the reduction of avoidable hospitalizations for patients with chronic heart conditions.

Mission and Vision

CardiaMetrics aims to provide actionable data to maintain cardiac condition stability, enabling healthcare professionals to monitor patients remotely and adjust treatments proactively. The company's vision is to integrate "health as a service" into its offerings, delivering practical and impactful innovations for patients and caregivers.

Industry Significance

The company addresses the global challenge of heart failure, a condition affecting approximately 64 million people worldwide. By offering a solution that combines minimally invasive subcutaneous sensors with artificial intelligence algorithms, CardiaMetrics aims to enhance patient outcomes and reduce the burden on healthcare systems.

Key Strategic Focus

Core Objectives

Prevent Cardiac Decompensations: Utilize continuous monitoring to detect early signs of deterioration in cardiac function.

Reduce Hospitalizations: Provide data-driven insights to adjust treatments, thereby decreasing the need for hospital admissions.

Enhance Patient Autonomy: Empower patients to manage their health effectively through integrated therapeutic education and automated monitoring.

Areas of Specialization

Telemonitoring: Implement remote monitoring solutions to track patient health metrics in real-time.

Medical Devices: Develop implantable sensors that provide continuous physiological data.

Artificial Intelligence: Employ AI algorithms to analyze data and predict cardiac events, facilitating personalized care.

Key Technologies Utilized

Subcutaneous Sensors: Minimally invasive devices that collect daily vital physiological data.

Intracardiac Pressure Monitoring: Measurement of intracardiac pressures to serve as a digital biomarker for heart failure monitoring.

IoT Integration: Connectivity solutions that transmit data to remote monitoring platforms for healthcare professionals.

Primary Markets Targeted

Chronic Heart Failure Patients: Individuals requiring long-term monitoring to manage their condition.

Cancer Patients on Cardiotoxic Treatments: Patients undergoing therapies that may adversely affect cardiac function.

Financials and Funding

Funding History

Initial Funding Round (September 2024): Raised €300,000 from private investors and leading cardiologists to accelerate technology development and prepare for clinical studies.

Second Funding Round (March 2026): Secured €1.7 million to support clinical and industrial growth, reflecting growing confidence in the company's vision.

Total Funds Raised

€2 million to date.

Notable Investors

Cardia Invest led both funding rounds, demonstrating strong support for the company's mission.

Utilization of Capital

Technology Development: Advancing the design and functionality of implantable sensors.

Clinical Studies: Collaborating with Caen University Hospital to conduct trials validating the clinical safety of the devices.

Regulatory Approvals: Preparing for FDA clearance and CE marking to facilitate market entry.

Pipeline Development

Key Pipeline Candidates

Implantable Sensors: Devices designed to monitor intracardiac pressures continuously.

Stages of Development

Clinical Trials: Planning the first human trials in partnership with Caen University Hospital, scheduled to begin in early 2025.

Target Conditions

Chronic Heart Failure: Focusing on early detection of decompensations to prevent hospitalizations.

Cardiotoxicity in Cancer Treatments: Monitoring cardiac function in patients undergoing therapies that may affect the heart.

Anticipated Milestones

2025-2026: Conducting clinical studies to gather data for regulatory submissions.

2027: Obtaining FDA clearance and CE marking for the implantable sensors.

Technological Platform and Innovation

Proprietary Technologies

Minimally Invasive Subcutaneous Sensors: Devices that provide continuous monitoring without requiring active patient engagement.

AI-Driven Predictive Algorithms: Analyzing data to predict cardiac events and inform therapeutic adjustments.

Significant Scientific Methods

Intracardiac Pressure Measurement: Utilizing intracardiac pressures as a digital biomarker for heart failure monitoring.

Remote Monitoring Integration: Combining IoT-enabled devices with telemedicine platforms for real-time data transmission.

Leadership Team

Executive Profiles

Thibault Parmentier – CEO & Co-Founder: With a PhD in Artificial Intelligence focusing on knowledge representation, Thibault has 15 years of experience in R&D and IT. He co-founded CardiaMetrics to address challenges in aging and dependency.

Cindy Michel – CSO & Co-Founder: A medical device engineer with a passion for cardiology, Cindy has experience in research, product development, and team management. She co-founded CardiaMetrics to transform heart failure management through technology.

Rémi Sabatier – CMO & Co-Founder: An interventional cardiologist specializing in medical telemonitoring, Rémi has been an active contributor to integrating telemonitoring into mainstream healthcare in France. He co-founded CardiaMetrics to bring effective solutions to heart failure management.

Mathieu Ruhlmann – CTO & Co-Founder: With 20 years of experience in software development, Mathieu has worked on various projects, including those involving artificial intelligence. He joined CardiaMetrics to develop meaningful solutions for society in the healthcare sector.

Cécilia Kroiss – COO: Specializing in managing the development of electro-medical, implantable, and software devices, Cécilia has held leadership roles in medical companies ranging from startups to large international groups. She joined CardiaMetrics to bring technology to serve the health of patients living with heart failure.

Competitor Profile

Market Insights and Dynamics

The global heart failure market is substantial, with approximately 64 million patients worldwide. The burden of heart failure is significant, with 1.27 million hospitalizations in the U.S. in 2018 and an estimated cost of $31 billion, projected to double by 2030.

Competitor Analysis

JenaValve: A competitor in the healthcare equipment sector, JenaValve operates in a similar space, focusing on heart valve technologies.

ICS: Another competitor in the healthcare equipment industry, ICS specializes in medical devices and services.

HLT: Operating within the healthcare equipment sector, HLT focuses on medical technologies and services.

Strategic Collaborations and Partnerships

CardiaMetrics has partnered with Caen University Hospital to conduct its first clinical study, aiming to validate the clinical safety of its implantable sensors.

Operational Insights

CardiaMetrics differentiates itself by offering a minimally invasive, continuous monitoring solution that does not rely on patient actions, thereby reducing the mental burden associated with chronic disease management. The integration of AI-driven predictive algorithms further enhances the personalization of patient care.

Strategic Opportunities and Future Directions

The company plans to deploy its solution in North America and Europe, with clinical studies scheduled for 2025-2027 and the goal of obtaining FDA clearance and CE certification by 2028. This expansion presents opportunities to address the global need for effective heart failure management solutions.